Allogene (NASDAQ: ALLO) CFO gets major equity grants, sells shares for taxes

Rhea-AI Filing Summary

Allogene Therapeutics’ chief financial officer Geoffrey M. Parker reported routine equity compensation activity and a tax-related share sale. On February 2, 2026, he sold 24,001 shares of common stock at a weighted average price of $1.76 solely to cover tax withholding on vesting restricted stock units, under a mandated “sell to cover” arrangement. Following this, he directly owned 1,252,795 common shares. On the same date, he received a stock option to buy 539,072 shares at an exercise price of $1.87 per share, vesting 25% on February 2, 2027 and the rest in 36 monthly installments. He also received 152,480 restricted stock units, each equal to one share of common stock, vesting in four equal annual installments starting February 2, 2026, subject to continued service.

Insider Trade Summary

Net Seller: 24,001 shares ($42,242)

Net Sell 3 txns

Insider Parker Geoffrey M.

Role CHIEF FINANCIAL OFFICER

Sold 24,001 shs ($42K)

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to buy)	539,072	$0.00	--
Grant/Award	Restricted Stock Unit	152,480	$0.00	--
Sale	Common Stock	24,001	$1.76	$42K

Holdings After Transaction: Stock Option (Right to buy) — 539,072 shares (Direct); Restricted Stock Unit — 152,480 shares (Direct); Common Stock — 1,252,795 shares (Direct)

Footnotes (1)

1. Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.71 to $1.83, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. 25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter. Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parker Geoffrey M.

(Last) (First) (Middle)

210 EAST GRAND AVE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Allogene Therapeutics, Inc. [ ALLO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		S		24,001(1)	D	$1.76(2)	1,252,795	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	$1.87	02/02/2026		A		539,072		(3)	02/02/2036	Common Stock	539,072	$0	539,072	D
Restricted Stock Unit	(4)	02/02/2026		A		152,480		(4)	(4)	Common Stock	152,480	$0	152,480	D

Explanation of Responses:

1. Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.71 to $1.83, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

3. 25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter.

4. Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date.

Remarks:

	/s/Earl Douglas, Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did ALLO’s CFO report on February 2, 2026?

Allogene Therapeutics’ CFO Geoffrey M. Parker reported three transactions on February 2, 2026: a sale of 24,001 common shares to cover tax withholding, a grant of 539,072 stock options, and a grant of 152,480 restricted stock units, all held directly.

Why did Allogene Therapeutics (ALLO) CFO sell 24,001 shares of common stock?

The 24,001 shares were sold solely to cover tax withholding obligations from vesting restricted stock units. The company’s equity plan mandates a “sell to cover” transaction, so this did not represent a discretionary trade by the CFO in the open market.

What equity awards did ALLO grant to its CFO on February 2, 2026?

On February 2, 2026, the CFO received stock options for 539,072 shares at a $1.87 exercise price and 152,480 restricted stock units. Both awards are subject to specific multi‑year vesting schedules tied to continued service with Allogene Therapeutics.

How do the new stock options for ALLO’s CFO vest over time?

The 539,072 stock options vest 25% on February 2, 2027. The remaining 75% then vest in 36 equal monthly installments, creating a four‑year vesting period that encourages long-term alignment with Allogene Therapeutics’ performance and tenure.

What is the vesting schedule for ALLO CFO’s 152,480 restricted stock units?

The 152,480 RSUs vest in four equal annual installments starting February 2, 2026. Each restricted stock unit converts into one share of Allogene Therapeutics common stock, contingent on the CFO’s continued service through each vesting date.

How many Allogene Therapeutics shares does the CFO own after the reported sale?

After selling 24,001 shares to cover tax withholding, the CFO directly owned 1,252,795 shares of Allogene Therapeutics common stock. This figure reflects his beneficial ownership immediately following the February 2, 2026 tax-related sale transaction.